Jason Haas

Insider Reports History

Entity
Individual
Location
C/O Syros Pharmaceuticals, Inc., 35 Cambridgepark Drive, Cambridge, Massachusetts
Signature
By: /s/ Andrew Reardon, Attorney-in-Fact For: Jason Haas
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Jason Haas:

Stock Role Class Num Shares Value Price $ Report Date Ownership
LIGAND PHARMACEUTICALS INC Director Common Stock 5.4K $468K $86.65 Jun 14, 2024 Direct
Syros Pharmaceuticals, Inc. Chief Financial Officer Restricted Stock Units 26.7K $137K $5.12 Mar 31, 2024 Direct
Syros Pharmaceuticals, Inc. Chief Financial Officer Common Stock 24.6K $126K $5.12 Apr 1, 2024 Direct
LIGAND PHARMACEUTICALS INC Director Non-Qualified Stock Option (right to buy) 5.44K Jun 14, 2024 Direct

Insider Reports Filed by Jason Haas

Symbol Company Period Transactions Value $ Form Type Date Filed Role
LGND LIGAND PHARMACEUTICALS INC Jun 14, 2024 2 $0 4 Jun 18, 2024 Director
SYRS Syros Pharmaceuticals, Inc. Mar 31, 2024 5 -$24.2K 4 Apr 2, 2024 Chief Financial Officer
SYRS Syros Pharmaceuticals, Inc. Oct 31, 2023 3 -$14K 4 Nov 2, 2023 Chief Financial Officer
LGND LIGAND PHARMACEUTICALS INC Jun 9, 2023 2 $0 4 Jun 13, 2023 Director
SYRS Syros Pharmaceuticals, Inc. Mar 31, 2023 3 -$1.61K 4 Apr 4, 2023 Chief Financial Officer
SYRS Syros Pharmaceuticals, Inc. Feb 16, 2023 1 $0 4 Feb 21, 2023 Chief Financial Officer
SYRS Syros Pharmaceuticals, Inc. Oct 6, 2022 2 $0 4 Oct 11, 2022 Chief Financial Officer
LGND LIGAND PHARMACEUTICALS INC Jun 29, 2022 2 $0 4 Jun 30, 2022 Director
LGND LIGAND PHARMACEUTICALS INC Jun 29, 2022 0 $0 3 Jun 29, 2022 Director
SYRS Syros Pharmaceuticals, Inc. Feb 15, 2022 2 $0 4 Feb 17, 2022 Chief Financial Officer
SYRS Syros Pharmaceuticals, Inc. Oct 12, 2021 1 $0 4 Oct 13, 2021 Chief Financial Officer
SYRS Syros Pharmaceuticals, Inc. Oct 12, 2021 0 $0 3 Oct 13, 2021 Chief Financial Officer